Table 2.
Overall survival (OS) | ||||
---|---|---|---|---|
Univariate | Multivariate | |||
HR (95% CI) | P | HR (95% CI) | P | |
Age | ||||
< 65 y | 1 | |||
≥ 65 y | 1.65 (0.93–2.27) | 0.126 | ||
Gender | ||||
Male | 1 | |||
Female | 1.27 (0.83–2.01) | 0.149 | ||
Location | ||||
Left | 1 | |||
Others | 0.82 (0.56–1.41) | 0.632 | ||
T stage | ||||
T1 + T2 | 1 | |||
T3 + T4 | 1.72 (0.52–5.29) | 0.391 | ||
N stage | ||||
N0 | 1 | 1 | ||
N1 + N2 | 6.71 (3.91–11.68) | <0.001* | 0.35 (0.04–1.92) | 0.163 |
AJCC stage | ||||
II | 1 | 1 | ||
III | 5.47 (4.25–10.27) | <0.001* | 18.38 (2.93–152.17) | 0.008* |
Histologic grade | ||||
Well Differentiated | 1 | 1 | ||
Poorly differentiated | 3.42 (1.98–5.24) | <0.001* | 2.34 (1.36–3.57) | 0.316 |
Venous & Lymphatic invasion | ||||
No | 1 | |||
Yes | 0.75 (0.37–0.95) 0.271 | |||
Peritoneal Dissemination | ||||
Absent | 1 | |||
Present | 0.52 (0.24–0.82) | 0.493 | ||
Liver Metastsis | ||||
Negative | 1 | 1 | ||
Positive Multinodular | 0.48 (0.29–0.81) | 0.001* | 0.59 (0.36–0.98) 0.024* | |
MiR-19b-3p | ||||
Low | 1 | 1 | ||
High | 2.79 (1.80–4.67) | <0.001* | 2.23 (1.42–3.58) | 0.008* |
HR: Hazard ratio; CI: Confidence interval
*P < 0.05 was considered significant